UPLOAD Filing
Biodexa Pharmaceuticals Plc
Date: Sept. 29, 2025 · CIK: 0001643918 · Accession: 0000000000-25-010576
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-290554
Letter
Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-3 Filed September 26, 2025 File No. 333-290554 Dear Stephen Stamp:
September 29, 2025
Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jason S. McCaffrey, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 29, 2025 Stephen Stamp Chief Executive Officer Biodexa Pharmaceuticals PLC 1 Caspian Point Caspian Way Cardiff, CF10 4DQ United Kingdom Re: Biodexa Pharmaceuticals PLC Registration Statement on Form F-3 Filed September 26, 2025 File No. 333-290554 Dear Stephen Stamp: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jason S. McCaffrey, Esq. </TEXT> </DOCUMENT>